Mimura et al. report findings from a single arm, phase I/II study of combined radiation and anti-PD-1 therapy in patients with advanced or recurrent gastric cancer. Combination therapy achieves a disease control rate of 22.5% for non-irradiated lesions via an abscopal effect, or 40% for irradiated lesions, and a median survival time of 230 days.
- Kosaku Mimura
- Takashi Ogata
- Koji Kono
